Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Interim Management Statement

22 May 2012 11:15

RNS Number : 8383D
Flying Brands Limited
22 May 2012
 



22 May 2012

 

 

FLYING BRANDS LIMITED

 

Trading Update

 

As announced on 1 May, we have now completed the disposals of our Gifts Division and of the Garden Bird Supplies, Garden Centre Online and Listen2 businesses ( together the "Sold Businesses").The business of the Group now comprises the Gardening Direct retail business, the Growing and Live Despatch business (GLD) and the freehold property at Retreat Farm. We are reporting today Group orders for the three month period to 31 March 2012 and for these purposes the Gardening Direct retail business and GLD are grouped together as the "Garden Division".

 

Overall Group Orders for the period to 31 March 2012 were £7.0m (2011: £10.8m). Orders for the Garden Division for the period were £3.8m (2011: £5.5m). Orders for the Sold Businesses for the period were £3.2 m (£5.3 m).

 

The Garden Division continues to face a number of challenges. The gardening industry generally this year has suffered as a result of a combination of poor weather and the continuing uncertain consumer outlook. In addition, we and our principal competitors have suffered as a result of the abolition of Low Value Consignment Relief earlier this year. We believe that the resulting increase in prices did have the effect of reducing demand and we, along with most of our competitors, have had to respond by reducing prices in the latter half of the season.

 

Our restructuring programme to cut central overheads, announced with our annual results on 30 April, is proceeding according to plan. We are continuing discussions with a number of prospective purchasers of our gardening businesses and will provide an update when appropriate. 

 

 

For further information, please contact:

 

Flying Brands Limited 01245 228 300

Stephen Cook, Chief Executive

Stuart Dootson, Group Finance Director

Smithfield Consultants 020 7360 4900

John Kiely

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBLLFLLEFFBBX
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.